Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway

Background: Deferoxamine (DFO) is a commonly used iron chelator, which can reduce the iron levels in cells. DFO is normally used to treat iron-overload disease, including some types of cancer. However, our previous studies revealed that DFO treatment significantly increased the iron concentrations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chunli, Liu, Ping, Duan, Xiaoyue, Cheng, Man, Xu, Lisa X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549404/
https://www.ncbi.nlm.nih.gov/pubmed/31213851
http://dx.doi.org/10.2147/OTT.S193507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549404/
https://www.ncbi.nlm.nih.gov/pubmed/31213851
http://dx.doi.org/10.2147/OTT.S193507

Ejemplares similares